NCT06891170

Brief Summary

In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 7, 2021

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 14, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 21, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 24, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
Last Updated

April 30, 2025

Status Verified

March 1, 2025

Enrollment Period

3.3 years

First QC Date

March 21, 2025

Last Update Submit

April 29, 2025

Conditions

COVID 19

Outcome Measures

Primary Outcomes (1)

  • Optimization of the method to obtain human mAbs neutralizing COVID-19.

    From enrollment to 24 weeks

Study Arms (1)

Vaccinated or recovered subjects from COVID-19

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Vaccinated or recovered subjects from COVID-19

You may qualify if:

  • Age \>18 at time of signing informed consent form
  • Signed informed consent form

You may not qualify if:

  • Ongoing drug abuse
  • Active or history of neoplastic malignancy
  • Active autoimmune disease ongoing treatment with immunosuppressive therapy
  • Ischemic heart disease
  • Evidence of positive HIV, HCV, HBV test
  • Diabetes
  • Failure to sign informed consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Pavia, 27100, Italy

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 21, 2025

First Posted

March 24, 2025

Study Start

July 7, 2021

Primary Completion

October 14, 2024

Study Completion

March 31, 2025

Last Updated

April 30, 2025

Record last verified: 2025-03

Locations

IT(1)